Quarterly ResultAug 5, 2026, 04:15 PM
Ginkgo Bioworks Q2 Revenue $20M, down 48%; Wins Gov't Lab Contracts
AI Summary
Ginkgo Bioworks reported Q2 2026 revenue of $20 million, a 48% decrease year-over-year, with a GAAP net loss of ($57) million and Adjusted EBITDA loss of ($36) million. Despite the financial decline, the company announced significant strategic wins, including government contracts to build autonomous labs at MIT, Caltech, Northwestern, and the University of Maryland. Ginkgo also highlighted the rapid scaling of its Nebula autonomous lab and the successful launch of its ADME-One service, which has already secured 17 customers.
Key Highlights
- Q2 2026 Revenue decreased 48% to $20 million from $39 million YoY.
- Q2 2026 GAAP net loss from continuing operations was ($57) million.
- Q2 2026 Adjusted EBITDA was ($36) million, up from ($25) million loss YoY.
- Cash, cash equivalents, and marketable securities totaled $302 million as of June 30, 2026.
- Won government contracts to build autonomous labs at MIT, Caltech, Northwestern, and UMD.
- Nebula autonomous lab is scaling rapidly, increasing devices in Q3.
- ADME-One service signed 17 customers in 6 weeks, 10X cheaper than competitors.
- Reaffirms full-year 2026 total cash burn guidance of ($150)-($125) million.
Price Impact
More from DNA